{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T17:09:28Z","timestamp":1781716168827,"version":"3.54.5"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T00:00:00Z","timestamp":1742860800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T00:00:00Z","timestamp":1742860800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Peking University First Hospital Research Seed Fund","award":["2024SF57"],"award-info":[{"award-number":["2024SF57"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"DOI":"10.1186\/s12957-025-03753-x","type":"journal-article","created":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T04:16:20Z","timestamp":1742876180000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Does concomitant ductal carcinoma in situ influence the prognostic outcome after neoadjuvant therapy in triple-negative invasive ductal carcinoma?"],"prefix":"10.1186","volume":"23","author":[{"given":"Sicheng","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zehao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Teng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,25]]},"reference":[{"issue":"10087","key":"3753_CR1","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1016\/S0140-6736(16)32454-0","volume":"89","author":"C Denkert","year":"2017","unstructured":"Denkert C, Liedtke C, Tutt A, et al. Molecular alterations in triple-negative breast cancer-the road to new treatment strategies. Lancet. 2017;89(10087):2430\u201342.","journal-title":"Lancet"},{"issue":"5","key":"3753_CR2","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.clbc.2020.12.011","volume":"21","author":"R Mahtani","year":"2021","unstructured":"Mahtani R, Kittaneh M, Kalinsky K, et al. Advances in therapeutic approaches for Triple-Negative breast cancer. Clin Breast Cancer. 2021;21(5):383\u201390.","journal-title":"Clin Breast Cancer"},{"issue":"2","key":"3753_CR3","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1158\/2159-8290.CD-18-1177","volume":"9","author":"AC Garrido-Castro","year":"2019","unstructured":"Garrido-Castro AC, Lin NU, Polyak K. Insights into molecular classifications of Triple-Negative breast cancer: improving patient selection for treatment. Cancer Discov. 2019;9(2):176\u201398.","journal-title":"Cancer Discov"},{"key":"3753_CR4","unstructured":"Galindo Garc\u00eda C, D\u00edaz Acedo R, Artacho Criado S et al. Effectiveness and safety of neoadjuvant therapy in triple-negative breast cancer in a real-world population. Farm Hosp. 2024;S1130-6343(24)00050\u2013\u20093."},{"issue":"2","key":"3753_CR5","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s10549-023-07114-8","volume":"203","author":"C Rogers","year":"2024","unstructured":"Rogers C, Cobb AN, Lloren JIC, et al. National trends in neoadjuvant chemotherapy utilization in patients with early-stage node-negative triple-negative breast cancer: the impact of the CREATE-X trial. Breast Cancer Res Treat. 2024;203(2):317\u201328.","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"3753_CR6","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s13148-015-0094-0","volume":"7","author":"KC Johnson","year":"2015","unstructured":"Johnson KC, Koestler DC, Fleischer T, et al. DNA methylation in ductal carcinoma in situ related with future development of invasive breast cancer. Clin Epigenetics. 2015;7(1):75.","journal-title":"Clin Epigenetics"},{"issue":"10","key":"3753_CR7","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.clon.2017.06.003","volume":"9","author":"H Cain","year":"2017","unstructured":"Cain H, Macpherson IR, Beresford M, et al. Neoadjuvant therapy in early breast cancer: treatment considerations and common debates in practice. Clin Oncol (R Coll Radiol). 2017;9(10):642\u201352.","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"8","key":"3753_CR8","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.ejso.2017.04.011","volume":"43","author":"H Goldberg","year":"2017","unstructured":"Goldberg H, Zandbank J, Kent V, et al. Chemotherapy May eradicate ductal carcinoma in situ (DCIS) but not the associated microcalcifications. Eur J Surg Oncol. 2017;43(8):1415\u201320.","journal-title":"Eur J Surg Oncol"},{"issue":"1","key":"3753_CR9","doi-asserted-by":"crossref","first-page":"9934","DOI":"10.1038\/s41598-019-46309-2","volume":"9","author":"AJ Kole","year":"2019","unstructured":"Kole AJ, Park HS, Johnson SB, et al. Overall survival is improved when DCIS accompanies invasive breast cancer. Sci Rep. 2019;9(1):9934.","journal-title":"Sci Rep"},{"issue":"1","key":"3753_CR10","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/his.12796","volume":"68","author":"JM Pang","year":"2016","unstructured":"Pang JM, Gorringe KL, Fox SB. Ductal carcinoma in situ-update on risk assessment and management. Histopathology. 2016;68(1):96\u2013109.","journal-title":"Histopathology"},{"issue":"2","key":"3753_CR11","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/jso.20242","volume":"90","author":"M Dzierzanowski","year":"2005","unstructured":"Dzierzanowski M, Melville KA, Barnes PJ, et al. Ductal carcinoma in situ in core biopsies containing invasive breast cancer: correlation with extensive intraductal component and lumpectomy margins. J Surg Oncol. 2005;90(2):71\u20136.","journal-title":"J Surg Oncol"},{"issue":"3","key":"3753_CR12","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.clbc.2020.01.011","volume":"20","author":"J Hu","year":"2020","unstructured":"Hu J, Fung MW, et al. Improved prognostication for the updated AJCC breast cancer pathological prognostic staging varied in Higher-Stage groups. Clin Breast Cancer. 2020;20(3):253\u2013e2617.","journal-title":"Clin Breast Cancer"},{"key":"3753_CR13","doi-asserted-by":"crossref","first-page":"13","DOI":"10.21037\/tbcr-22-21","volume":"3","author":"Z Jiang","year":"2022","unstructured":"Jiang Z, Li J, Chen J, et al. Chinese society of clinical oncology (CSCO) breast cancer guidelines 2022. Transl Breast Cancer Res. 2022;3:13.","journal-title":"Transl Breast Cancer Res"},{"issue":"1\u20132","key":"3753_CR14","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.cell.2017.12.007","volume":"172","author":"AK Casasent","year":"2018","unstructured":"Casasent AK, Schalck A, Gao R, et al. Multiclonal invasion in breast tumors identified by topographic single cell sequencing. Cell. 2018;172(1\u20132):205\u2013e21712.","journal-title":"Cell"},{"issue":"1","key":"3753_CR15","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/tbj.12359","volume":"21","author":"MD Lagios","year":"2015","unstructured":"Lagios MD, Silverstein MJ. Ductal carcinoma in situ: recent history and areas of controversy. Breast J. 2015;21(1):21\u20136.","journal-title":"Breast J"},{"issue":"1","key":"3753_CR16","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s13058-021-01494-9","volume":"24","author":"A Niwi\u0144ska","year":"2021","unstructured":"Niwi\u0144ska A, Olszewski WP. The role of stromal immune microenvironment in the progression of ductal carcinoma in situ (DCIS) to invasive breast cancer. Breast Cancer Res. 2021;24(1):118.","journal-title":"Breast Cancer Res"},{"issue":"6","key":"3753_CR17","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1097\/PAI.0000000000001028","volume":"30","author":"MM Dawoud","year":"2022","unstructured":"Dawoud MM, Jones DT, Chelala C, Abdou AG, Dreger SA, Asaad N, Abd El-Wahed M, Jones L. Expression profile of myoepithelial cells in DCIS: do they change from protective angels to wicked witches?? Appl Immunohistochem Mol Morphol. 2022;30(6):397\u2013409.","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"1","key":"3753_CR18","doi-asserted-by":"crossref","first-page":"3399","DOI":"10.1038\/s41467-022-30573-4","volume":"13","author":"CA Rebbeck","year":"2022","unstructured":"Rebbeck CA, Xian J, Bornel\u00f6v S, et al. Gene expression signatures of individual ductal carcinoma in situ lesions identify processes and biomarkers associated with progression towards invasive ductal carcinoma. Nat Commun. 2022;13(1):3399.","journal-title":"Nat Commun"},{"issue":"4","key":"3753_CR19","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s10911-018-9414-2","volume":"23","author":"RS DeVaux","year":"2018","unstructured":"DeVaux RS, Herschkowitz JI. Beyond DNA: the role of epigenetics in the premalignant progression of breast cancer. J Mammary Gland Biol Neoplasia. 2018;23(4):223\u201335.","journal-title":"J Mammary Gland Biol Neoplasia"},{"issue":"2","key":"3753_CR20","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s10549-023-07012-z","volume":"201","author":"RAW Ploumen","year":"2023","unstructured":"Ploumen RAW, Claassens EL, Kooreman LFS, et al. Pathologic complete response of ductal carcinoma in situ to neoadjuvant systemic therapy in HER2-positive invasive breast cancer patients: a nationwide analysis. Breast Cancer Res Treat. 2023;201(2):227\u201335.","journal-title":"Breast Cancer Res Treat"},{"issue":"9","key":"3753_CR21","doi-asserted-by":"crossref","first-page":"e1646","DOI":"10.1002\/cnr2.1646","volume":"5","author":"WP Lee","year":"2022","unstructured":"Lee WP, Shetty SS, Seah CMJ, et al. Does concomitant ductal carcinoma in situ affect the clinical outcome in breast cancer patients with invasive ductal carcinoma: an Asian perspective. Cancer Rep (Hoboken). 2022;5(9):e1646.","journal-title":"Cancer Rep (Hoboken)"},{"issue":"1","key":"3753_CR22","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s10549-021-06235-2","volume":"189","author":"EJ Groen","year":"2021","unstructured":"Groen EJ, van der Noordaa MEM, Schaapveld M, et al. Pathologic response of ductal carcinoma in situ to neoadjuvant systemic treatment in HER2-positive breast cancer. Breast Cancer Res Treat. 2021;189(1):213\u201324.","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"3753_CR23","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s10549-011-1621-0","volume":"132","author":"G von Minckwitz","year":"2012","unstructured":"von Minckwitz G, Darb-Esfahani S, Loibl S, et al. Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy\/trastuzumab treatment in early breast cancer\u2013results from the GeparQuattro study (GBG 40). Breast Cancer Res Treat. 2012;132(3):863\u201370.","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"3753_CR24","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s00428-018-2416-z","volume":"473","author":"S Takahashi","year":"2018","unstructured":"Takahashi S, Thike AA, Koh VCY, et al. Triple-negative and HER2 positive ductal carcinoma in situ of the breast: characteristics, behavior, and biomarker profile. Virchows Arch. 2018;473(3):275\u201383.","journal-title":"Virchows Arch"},{"issue":"50","key":"3753_CR25","doi-asserted-by":"crossref","first-page":"e23487","DOI":"10.1097\/MD.0000000000023487","volume":"99","author":"X Guan","year":"2020","unstructured":"Guan X, Xu G, Shi A, et al. Comparison of clinicopathological characteristics and prognosis among patients with pure invasive ductal carcinoma, invasive ductal carcinoma coexisted with invasive micropapillary carcinoma, and invasive ductal carcinoma coexisted with ductal carcinoma in situ: A retrospective cohort study. Med (Baltim). 2020;99(50):e23487.","journal-title":"Med (Baltim)"},{"issue":"7","key":"3753_CR26","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1007\/s00432-019-02930-2","volume":"145","author":"CW Goh","year":"2019","unstructured":"Goh CW, Wu J, Ding S, et al. Invasive ductal carcinoma with coexisting ductal carcinoma in situ (IDC\/DCIS) versus pure invasive ductal carcinoma (IDC): a comparison of clinicopathological characteristics, molecular subtypes, and clinical outcomes. J Cancer Res Clin Oncol. 2019;145(7):1877\u201386.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"8","key":"3753_CR27","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1136\/jclinpath-2012-201428","volume":"66","author":"AA Thike","year":"2013","unstructured":"Thike AA, Iqbal J, Cheok PY, et al. Ductal carcinoma in situ associated with triple negative invasive breast cancer: evidence for a precursor-product relationship. J Clin Pathol. 2013;66(8):665\u201370.","journal-title":"J Clin Pathol"},{"issue":"13","key":"3753_CR28","doi-asserted-by":"crossref","first-page":"11181","DOI":"10.1007\/s00432-023-04895-9","volume":"149","author":"Y Liu","year":"2023","unstructured":"Liu Y, Yu T. Clinicopathological characteristics and prognosis of triple-negative breast cancer invasive ductal carcinoma with ductal carcinoma in situ. J Cancer Res Clin Oncol. 2023;149(13):11181\u201391.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"8","key":"3753_CR29","doi-asserted-by":"crossref","first-page":"5423","DOI":"10.1007\/s00330-023-09547-7","volume":"33","author":"RAW Ploumen","year":"2023","unstructured":"Ploumen RAW, de Mooij CM, Gommers S, et al. Imaging findings for response evaluation of ductal carcinoma in situ in breast cancer patients treated with neoadjuvant systemic therapy: a systematic review and meta-analysis. Eur Radiol. 2023;33(8):5423\u201335.","journal-title":"Eur Radiol"},{"issue":"10","key":"3753_CR30","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.1245\/s10434-019-07533-2","volume":"26","author":"S Sun","year":"2019","unstructured":"Sun S, van la Parra RFD, Rauch GM, et al. Patient selection for clinical trials eliminating surgery for HER2-Positive breast cancer treated with neoadjuvant systemic therapy. Ann Surg Oncol. 2019;26(10):3071\u20139.","journal-title":"Ann Surg Oncol"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-025-03753-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-025-03753-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-025-03753-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T04:16:55Z","timestamp":1742876215000},"score":1,"resource":{"primary":{"URL":"https:\/\/wjso.biomedcentral.com\/articles\/10.1186\/s12957-025-03753-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,25]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3753"],"URL":"https:\/\/doi.org\/10.1186\/s12957-025-03753-x","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,25]]},"assertion":[{"value":"23 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All enrolled patients sign written informed consent to participate in the study. The study was conducted per STARD reporting guidelines. All the procedures followed the ethical standards of the World Medical Association Declaration of Helsinki. The Institutional Review Board Committee of the institutions approved this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"101"}}